CN101048414B - 用于治疗精神障碍的稠合的三环衍生物 - Google Patents

用于治疗精神障碍的稠合的三环衍生物 Download PDF

Info

Publication number
CN101048414B
CN101048414B CN2005800372427A CN200580037242A CN101048414B CN 101048414 B CN101048414 B CN 101048414B CN 2005800372427 A CN2005800372427 A CN 2005800372427A CN 200580037242 A CN200580037242 A CN 200580037242A CN 101048414 B CN101048414 B CN 101048414B
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
acceptable salt
compound according
methyl
ethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800372427A
Other languages
English (en)
Chinese (zh)
Other versions
CN101048414A (zh
Inventor
乔纳森·本特利
马库斯·伯高尔
巴巴拉·伯塔尼
马泰奥·比亚格蒂
曼纽拉·博里洛
斯蒂文·M·布罗米奇
马西莫·贾诺蒂
恩里卡·格兰西
科林·P·莱斯利
亚历山德拉·帕斯夸雷洛
瓦莱里娅·朱克奇利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0419315A external-priority patent/GB0419315D0/en
Priority claimed from GB0507386A external-priority patent/GB0507386D0/en
Priority claimed from GB0515010A external-priority patent/GB0515010D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CN101048414A publication Critical patent/CN101048414A/zh
Application granted granted Critical
Publication of CN101048414B publication Critical patent/CN101048414B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CN2005800372427A 2004-08-31 2005-08-29 用于治疗精神障碍的稠合的三环衍生物 Expired - Fee Related CN101048414B (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0419315A GB0419315D0 (en) 2004-08-31 2004-08-31 Compounds
GB0419315.7 2004-08-31
GB0507386A GB0507386D0 (en) 2005-04-12 2005-04-12 Compounds
GB0507386.1 2005-04-12
GB0515010A GB0515010D0 (en) 2005-07-21 2005-07-21 Compounds
GB0515010.7 2005-07-21
PCT/EP2005/009379 WO2006024517A1 (en) 2004-08-31 2005-08-29 Fused tricyclic derivatives for the treatment of psychotic disorders

Publications (2)

Publication Number Publication Date
CN101048414A CN101048414A (zh) 2007-10-03
CN101048414B true CN101048414B (zh) 2011-09-07

Family

ID=35106764

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800372427A Expired - Fee Related CN101048414B (zh) 2004-08-31 2005-08-29 用于治疗精神障碍的稠合的三环衍生物

Country Status (17)

Country Link
US (1) US20120022056A1 (https=)
EP (1) EP1786822A1 (https=)
JP (1) JP2008511574A (https=)
KR (1) KR20070057885A (https=)
CN (1) CN101048414B (https=)
AR (1) AR053307A1 (https=)
AU (1) AU2005279278A1 (https=)
BR (1) BRPI0514377A (https=)
CA (1) CA2578781A1 (https=)
IL (1) IL181387A (https=)
MA (1) MA28871B1 (https=)
MX (1) MX2007002548A (https=)
NO (1) NO20071326L (https=)
NZ (1) NZ553506A (https=)
PE (1) PE20060653A1 (https=)
TW (1) TW200619221A (https=)
WO (1) WO2006024517A1 (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0316915D0 (en) 2003-07-18 2003-08-20 Glaxo Group Ltd Compounds
US7898642B2 (en) 2004-04-14 2011-03-01 Asml Netherlands B.V. Lithographic apparatus and device manufacturing method
JP4324221B2 (ja) * 2005-08-26 2009-09-02 株式会社医薬分子設計研究所 Ｐｐａｒアゴニスト活性を有する誘導体
JP2009523820A (ja) * 2006-01-23 2009-06-25 アミラ ファーマシューティカルス，インコーポレーテッド ５−リポキシゲナーゼの三環系抑制剤
US7501438B2 (en) 2006-07-07 2009-03-10 Forest Laboratories Holdings Limited Pyridoimidazole derivatives
CA2662080C (en) 2006-09-07 2012-07-17 F. Hoffmann-La Roche Ag A process for the manufacture of snac (salcaprozate sodium)
JP2010504367A (ja) 2006-09-26 2010-02-12 グラクソ グループ リミテッド 性機能障害、認知障害、精神病性障害、不安、鬱病などを処置するための５ｈｔ１ａ受容体モジュレーターとしての５−｛２−［４−（２−メチル−５−キノリニル）−ｌ−ピペリジニル］エチル｝キノリノン誘導体
AU2008223348A1 (en) * 2007-03-07 2008-09-12 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors containing a heterocyclic moiety
EP2070933A1 (en) 2007-12-07 2009-06-17 Laboratorios del Dr. Esteve S.A. Tricyclic triazolic compounds
GB0800840D0 (en) 2008-01-17 2008-02-27 Glaxo Group Ltd Novel salt
DK2268644T3 (da) 2008-03-05 2011-10-10 Boehringer Ingelheim Int Tricycliske pyridinderivater, medikamenter indeholdende sådanne forbindelser, deres anvendelse og fremgangsmåde til deres fremstilling
WO2010111626A2 (en) * 2009-03-27 2010-09-30 Takeda Pharmaceutical Company Limited Poly (adp-ribose) polymerase (parp) inhibitors
EA201201160A1 (ru) 2010-02-19 2013-04-30 Бёрингер Ингельхайм Интернациональ Гмбх Трициклические производные пиридина, лекарственные средства, содержащие такие соединения, их применение и способ их получения
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
WO2012154731A1 (en) * 2011-05-08 2012-11-15 Vanderbilt University Substituted 1h-pyrrolo[3,2-c]quinolin-4(5h)-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
JP5947382B2 (ja) 2011-08-17 2016-07-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング フロ［３，４−ｃ］キノリン誘導体、このような化合物を含む薬物、それらの使用及びそれらの調製方法
EP2792679A1 (en) * 2013-04-19 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Tricyclic triazolic compounds
JP6523267B2 (ja) * 2013-06-24 2019-05-29 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ Ｆｓｈｒの調節剤としてのイミダゾール化合物及びその使用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0887349A1 (en) * 1997-06-26 1998-12-30 Akzo Nobel N.V. Tetrahydroimidazo (2,1-a)isoquinoline derivatives
US6143767A (en) * 1996-08-14 2000-11-07 Pfizer Inc Piperidinylamino tricyclic compounds as substance P antagonists

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6919334B2 (en) * 2002-09-12 2005-07-19 Wyeth Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine
GB0227240D0 (en) * 2002-11-21 2002-12-31 Glaxo Group Ltd Compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6143767A (en) * 1996-08-14 2000-11-07 Pfizer Inc Piperidinylamino tricyclic compounds as substance P antagonists
EP0887349A1 (en) * 1997-06-26 1998-12-30 Akzo Nobel N.V. Tetrahydroimidazo (2,1-a)isoquinoline derivatives

Also Published As

Publication number Publication date
US20120022056A1 (en) 2012-01-26
EP1786822A1 (en) 2007-05-23
WO2006024517A1 (en) 2006-03-09
PE20060653A1 (es) 2006-09-27
IL181387A (en) 2011-10-31
KR20070057885A (ko) 2007-06-07
NO20071326L (no) 2007-05-03
CN101048414A (zh) 2007-10-03
MA28871B1 (fr) 2007-09-03
AR053307A1 (es) 2007-05-02
AU2005279278A1 (en) 2006-03-09
TW200619221A (en) 2006-06-16
CA2578781A1 (en) 2006-03-09
NZ553506A (en) 2010-02-26
IL181387A0 (en) 2007-07-04
BRPI0514377A (pt) 2008-06-24
MX2007002548A (es) 2007-04-24
JP2008511574A (ja) 2008-04-17

Similar Documents

Publication Publication Date Title
CN101048414B (zh) 用于治疗精神障碍的稠合的三环衍生物
CN104507939B (zh) 四氢吡唑并嘧啶化合物
CN110105346B (zh) 选择性取代的喹啉化合物
TWI431007B (zh) 作為α７菸鹼乙醯膽鹼受體配位體之啶化合物
CN105814054B (zh) 作为tnf活性调节剂的稠合咪唑和吡唑衍生物
US8097618B2 (en) Pyridine derivatives and their use in the treatment of psychotic disorders
CN102216297B (zh) (二氢)吡咯并[2，1-a]异喹啉类
TW201348226A (zh) 作為ｐｉｍ抑制劑之醯胺
WO2011012622A1 (en) Benzoxazinone derivatives for the treatment of glytl mediated disorders
CN110225911A (zh) 噁二唑酮瞬时受体电位通道抑制剂
US9376436B2 (en) 2-(pyridin-2yl)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulators
CN117999259A (zh) 铁死亡调节剂、其制备和用途
WO2023074847A1 (ja) 新規スピロ化合物
WO2009138393A1 (en) 5-[5-[2-(3,5-bis(trifluoromethyl)phenyl)-2-methylpropanoylmethylamino]-4-(4-fluoro-2-methylphenyl)]-2-pyridinyl-2-alkyl-prolinamide as nk1 receptor antagonists
CN102791718B (zh) 作为α-7烟碱乙酰胆碱受体配体的奎宁环化合物
CN101090902B (zh) Cgrp受体拮抗剂
RU2409582C2 (ru) Конденсированные трициклические производные для лечения психотических расстройств
CN116234550A (zh) 芳甲酰取代的三环化合物及其制法和用途
WO2010142652A1 (en) Imidazobenzazepine compounds for the treatment of central nervous system (cns) diseases
JP2024159693A (ja) 新規スピロ化合物を含有する医薬組成物
HK1197409B (en) 2,3-dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (pi3k) inhibitors for the treatment of e.g. rheumatoid arthritis
HK1197409A (en) 2,3-dihydro-benzo[1,4]oxazine derivatives and related compounds as phosphoinositide-3 kinase (pi3k) inhibitors for the treatment of e.g. rheumatoid arthritis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C17 Cessation of patent right
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20110907

Termination date: 20120829